PatientView | カナダの患者グループによるインサイト：価格決定の場への参加

患者グループの目標

以下のパーセンテージは、58の患者グループが規制当局とどのように関わり、患者の利益を擁護しているかを示しています。回答者は複数の分野で代表されている場合があるため、パーセンテージの合計が100%にならない場合があります。

インタラクション

患者グループが医薬品規制当局とどのように関わるか

目標の意味を確認する

36 メンション

9 メンション

6 メンション

4 メンション

2 メンション

アクションと支援活動

患者グループが医薬品へのアクセスを得る方法

目標の意味を確認する

17 メンション

14 メンション

7 メンション

2 メンション

英語のテキスト	治療領域	カテゴリ	患者数	ジオリーチ	規制当局との関与	回答者
We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions.	視覚障害 > 視覚障害	規制上のパートナーシップ > 規制機関との連携	Do not know	National	Sometimes	119063928324
Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services].	視覚障害 > 黄斑変性	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	Regional	Regularly	115043530962
INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	神経学的 > 多発性硬化症	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	National	Regularly	115059223657
Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare.	呼吸器 > COPD	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Sometimes	119013149214
Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions.	呼吸器 > 喘息とアレルギー	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119021123567
Canadian Drug Agency patient submissions.	呼吸器 > 喘息とアレルギー	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119021123567
HTA [Health Technology Assessment] submissions.	スキン > 皮膚疾患：ほとんどの種類	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119022981107
We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]).	がん > がん：血液	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	National	Regularly	119031899906
We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels.	消化器系 > 消化器系：ほとんどの種類	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119037340441
We do regular submissions for HTA [Health Technology Assessment].	消化器系 > 消化器系：ほとんどの種類	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119037340441
CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance].	心臓血管 > 心臓・循環器系の疾患	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	International	Sometimes	119040619515
Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	全般的な健康状態 > 全般的な健康状態	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	National	Sometimes	119042243488
Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada].	がん > がん：皮膚	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	5,000	National	Regularly	119042855470
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making.	患者擁護 > 健康活動家	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	We do not communicate with patients directly	National	Sometimes	119044376594
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints.	患者擁護 > 健康活動家	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	We do not communicate with patients directly	National	Sometimes	119044376594
Part of CDA [Canada’s Drug Agency] review process.	呼吸器 > 肺疾患	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	Regional	Rarely	119044465336
Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors.	レア > 希少疾患：その他	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	1,000	National	Sometimes	119045262810
Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government.	がん > がん：乳房	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119049015873
INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access.	がん > がん：ほとんどの種類	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	1,000	Regional	Sometimes	119050786265
Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers.	スキン > 脱毛症	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	5,000	National	Sometimes	119050829703
CDA [Canadian Drug Agency] submissions, working with each provincial formulary.	呼吸器 > 肺線維症	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119050864232
Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues.	がん > がん：血液	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	5,000	National	Regularly	119050868250
HTA [Health Technology Assessment] submissions for new treatments.	がん > がん：膀胱	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	National	Sometimes	119051388329
We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs.	視覚障害 > 視覚障害	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119061542318
We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	がん > がん：ほとんどの種類	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	1,000	National	Regularly	119068300611
Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years.	レア > ポンペ病	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100	National	Rarely	119070062251
We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency.	呼吸器 > 肺線維症	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119070095029
CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	がん > がん：大腸がん	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	10,000	National	Regularly	119070177334
Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care.	全般的な健康状態 > 肥満	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	International	Regularly	119071517799
CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services].	全般的な健康状態 > 肥満	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	100,000	National	Regularly	119072155321
HTA [Health Technology Assessment] assessments and reimbursement reviews.	患者教育 > 患者教育	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	Do not know	National	Sometimes	119073221885
We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently.	呼吸器 > 肺疾患	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	Do not know	National	Rarely	119074014255
Patient submissions to CDA [Canada's Drug Agency].	リウマチ性 > 全身性エリテマトーデス	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	We do not communicate with patients directly	National	Regularly	119076616920
We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss.	視覚障害 > 視覚障害	規制上のパートナーシップ > 医療技術評価（HTA）および償還審査への参加	Do not know	National	Regularly	119076796006
We fully support new technologies and therapies to Health Canada.	障害 > 障害：その他	規制上のパートナーシップ > マーケティング承認申請への貢献	5,000	National	Regularly	119070019511
Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees.	高齢者 > 高齢者	規制上のパートナーシップ > 政策立案者・規制当局との会議への出席・ファシリテーション	100,000	National	Regularly	119020601606
Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government.	がん > がん：乳房	規制上のパートナーシップ > 政策立案者・規制当局との会議への出席・ファシリテーション	100,000	National	Regularly	119049015873
Represent patient issues to regulators.	レア > 希少疾患：血液	規制上のパートナーシップ > 政策立案者・規制当局との会議への出席・ファシリテーション	We do not communicate with patients directly	National	Regularly	119078414468
Patients participate in Town Halls where some of these issues are addressed.	血液 > 鎌状赤血球症	規制上のパートナーシップ > 他の医療擁護者と	100	Regional	Rarely	119026823537
Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care.	視覚障害 > 黄斑変性	政策と法律への影響 > 医療政策と法律に影響を与える	100,000	Regional	Regularly	115043530962
We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc.	高齢者 > 高齢者	政策と法律への影響 > 医療政策と法律に影響を与える	10,000	National	Regularly	119044669631
HTA submissions, other public consultations, awareness-building.	スキン > 皮膚疾患：ほとんどの種類	政策と法律への影響 > 公聴会やパブリックコンサルテーションに参加する	100,000	National	Regularly	119022981107
Provincial Legislative Advocacy days yearly.	リウマチ性 > 強皮症	政策と法律への影響 > 公聴会やパブリックコンサルテーションに参加する	5,000	National	Regularly	119071951250
Media representation and direct advocacy to provincial Members of Parliament.	レア > まれな疾患：遺伝性	政策と法律への影響 > 国会議員や政治指導者を動員する	1,000	Regional	Sometimes	115035427287
Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees.	高齢者 > 高齢者	政策と法律への影響 > 国会議員や政治指導者を動員する	100,000	National	Regularly	119020601606
We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc.	高齢者 > 高齢者	政策と法律への影響 > 国会議員や政治指導者を動員する	10,000	National	Regularly	119044669631
Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use.	がん > がん：血液	政策と法律への影響 > 医療における障壁・異常への対処	1,000	National	Sometimes	119022124095
We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss.	視覚障害 > 視覚障害	政策と法律への影響 > 医療における障壁・異常への対処	Do not know	National	Regularly	119076796006
Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails.	がん > がん：血液	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	5,000	National	Sometimes	119020401468
... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies.	患者擁護 > 健康活動家	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	We do not communicate with patients directly	National	Sometimes	119044376594
We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy.	神経学的 > てんかん	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	5,000	Local	Regularly	119050807827
We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed.	がん > がん：ほとんどの種類	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	1,000	National	Regularly	119068300611
I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing.	がん > がん：血液	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	5,000	National	Regularly	119068939499
Mostly drug reimbursement approval, but that touches on pricing as well.	レア > ポンペ病	価格設定と手頃な価格の擁護 > 公正な医薬品価格の実現を推進する	100	National	Rarely	119070062251
Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails.	がん > がん：血液	価格設定と手頃な価格の擁護 > 価格審査委員会の交渉に参加する	5,000	National	Sometimes	119020401468
We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.].	免疫 > 原発性免疫不全症	価格設定と手頃な価格の擁護 > 価格審査委員会の交渉に参加する	5,000	National	Sometimes	119044550257
We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc.	高齢者 > 高齢者	価格設定と手頃な価格の擁護 > 価格審査委員会の交渉に参加する	10,000	National	Regularly	119044669631
... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence.	視覚障害 > 視覚障害	価格設定と手頃な価格の擁護 > 価格審査委員会の交渉に参加する	100,000	National	Regularly	119061542318
We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary.	がん > がん：血液	価格設定と手頃な価格の擁護 > メーカーからの販売価格引き下げの要請	10,000	National	Regularly	119031899906
We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance].	免疫 > 原発性免疫不全症	価格設定と手頃な価格の擁護 > 薬価の追跡・監視/医薬品不足	5,000	National	Sometimes	119044550257
We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy.	神経学的 > てんかん	価格設定と手頃な価格の擁護 > 薬価の追跡・監視/医薬品不足	5,000	Local	Regularly	119050807827
We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed.	がん > がん：ほとんどの種類	価格設定と手頃な価格の擁護 > 薬価の追跡・監視/医薬品不足	1,000	National	Regularly	119068300611
Patient group submissions—not specific to pricing itself, but to approvals for coverage.	メンタルヘルス > メンタルヘルス：気分障害	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	10,000	National	Rarely	119020492804
We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance].	免疫 > 原発性免疫不全症	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	5,000	National	Sometimes	119044550257
Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies.	神経学的 > てんかん	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	We do not communicate with patients directly	National	Regularly	119045277128
CDA [Canadian Drug Agency] submissions, working with each provincial formulary.	呼吸器 > 肺線維症	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	100,000	National	Regularly	119050864232
We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often.	視覚障害 > 視覚障害	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	Do not know	National	Sometimes	119063928324
Mostly drug reimbursement approval, but that touches on pricing as well.	レア > ポンペ病	価格設定と手頃な価格の擁護 > 製品の償還リスト/国家医薬品集への収載推進	100	National	Rarely	119070062251
HTA submissions, other public consultations, awareness-building.	スキン > 皮膚疾患：ほとんどの種類	価格設定と手頃な価格の擁護 > 啓発キャンペーンへの参加	100,000	National	Regularly	119022981107
Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use.	がん > がん：血液	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	1,000	National	Sometimes	119022124095
We don't provide information for drug pricing, just advocacy for drug approvals or access.	リウマチ性 > 全身性エリテマトーデス	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	5,000	Regional	No	119022371395
... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies.	患者擁護 > 健康活動家	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	We do not communicate with patients directly	National	Sometimes	119044376594
Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment].	レア > 希少疾患：その他	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	1,000	National	Sometimes	119045262810
Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access.	神経学的 > てんかん	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	We do not communicate with patients directly	National	Regularly	119045277128
INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access.	がん > がん：ほとんどの種類	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	1,000	Regional	Sometimes	119050786265
Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues.	がん > がん：血液	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	5,000	National	Regularly	119050868250
We frequently advocate for the approval of new drugs for market access.	視覚障害 > 視覚障害	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	Do not know	National	Sometimes	119063928324
… and have written numerous submissions to the authorities about drug access and pricing.	がん > がん：血液	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	5,000	National	Regularly	119068939499
Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care.	全般的な健康状態 > 肥満	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	100,000	International	Regularly	119071517799
Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment.	リウマチ性 > 全身性エリテマトーデス	アクセス経路の改善 > 医薬品・医療への公平なアクセスを促進する	We do not communicate with patients directly	National	Regularly	119076616920
We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc.	高齢者 > 高齢者	アクセス経路の改善 > より広いワクチンアクセスを推進する	10,000	National	Regularly	119044669631
We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces.	視覚障害 > 視覚障害	アクセス経路の改善 > アクセスと管理における格差への対処	100,000	National	Regularly	119061542318
There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients.	がん > がん：肉腫	アクセス経路の改善 > 希少・超希少疾患治療へのアクセス改善	5,000	National	Regularly	119078449674
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making.	患者擁護 > 健康活動家	エビデンスに基づく患者の意見 > 患者のインサイトを活用して意思決定に役立てる	We do not communicate with patients directly	National	Sometimes	119044376594
Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers.	スキン > 脱毛症	エビデンスに基づく患者の意見 > 患者のインサイトを活用して意思決定に役立てる	5,000	National	Sometimes	119050829703
Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years.	レア > ポンペ病	エビデンスに基づく患者の意見 > 患者のインサイトを活用して意思決定に役立てる	100	National	Rarely	119070062251
Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care.	全般的な健康状態 > 肥満	エビデンスに基づく患者の意見 > 患者のインサイトを活用して意思決定に役立てる	100,000	International	Regularly	119071517799
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints.	患者擁護 > 健康活動家	エビデンスに基づく患者の意見 > 規制当局にリアルワールドエビデンス（RWE）を提供する	We do not communicate with patients directly	National	Sometimes	119044376594
The lived experiences of patients are at the centre of Lupus Canada's work.	リウマチ性 > 全身性エリテマトーデス	エビデンスに基づく患者の意見 > 患者の体験談や生きた経験のナラティブを活用する	Do not know	National	Regularly	119041443233
Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	全般的な健康状態 > 全般的な健康状態	エビデンスに基づく患者の意見 > 患者の体験談や生きた経験のナラティブを活用する	10,000	National	Sometimes	119042243488
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints.	患者擁護 > 健康活動家	エビデンスに基づく患者の意見 > 患者の体験談や生きた経験のナラティブを活用する	We do not communicate with patients directly	National	Sometimes	119044376594
We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services].	がん > がん：ほとんどの種類	エビデンスに基づく患者の意見 > 患者の体験談や生きた経験のナラティブを活用する	1,000	National	Regularly	119068300611
We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services].	がん > がん：ほとんどの種類	エビデンスに基づく患者の意見 > 患者の体験談や生きた経験のナラティブを活用する	1,000	National	Regularly	119068300611
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints.	患者擁護 > 健康活動家	エビデンスに基づく患者の意見 > 調査/研究を実施してデータを生成する	We do not communicate with patients directly	National	Sometimes	119044376594
We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions.	視覚障害 > 視覚障害	エビデンスに基づく患者の意見 > 調査/研究を実施してデータを生成する	Do not know	National	Sometimes	119063928324
Representation, rights advocacy, and immigration support.	HIV > HIVと性の健康	機関ガバナンス > 政府の諮問機関における代表性を確保する	100	National	Regularly	115032094015
We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels.	消化器系 > 消化器系：ほとんどの種類	機関ガバナンス > 政府の諮問機関における代表性を確保する	100,000	National	Regularly	119037340441
... been invited to national roundtables by governments and also by pharma, etc.	高齢者 > 高齢者	機関ガバナンス > 政府の諮問機関における代表性を確保する	10,000	National	Regularly	119044669631
I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective.	がん > がん：血液	機関ガバナンス > 政府の諮問機関における代表性を確保する	5,000	National	Regularly	119068939499
There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw	がん > がん：肉腫	機関ガバナンス > 政府の諮問機関における代表性を確保する	5,000	National	Regularly	119078449674
Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access.	神経学的 > てんかん	機関ガバナンス > マルチステークホルダーネットワーク内での効果的な協働	We do not communicate with patients directly	National	Regularly	119045277128
Representation, rights advocacy, and immigration support.	HIV > HIVと性の健康	患者の権利の擁護/生活の質の向上 > 患者体験の保護・改善	100	National	Regularly	115032094015
We are a peer-led organization that advocates for one another on patients' rights, on care and treatment.	HIV > HIV	患者の権利の擁護/生活の質の向上 > 患者体験の保護・改善	1,000	Local	Regularly	119045557717

カナダ

調査のインサイト

患者グループの声

患者グループの目標

患者グループが医薬品規制当局とどのように関わるか

患者グループが医薬品へのアクセスを得る方法

完全な調査結果にアクセスする

サンプルレポートをダウンロード